Avalo Therapeutics, Inc. - 10-Q Filing
Avalo Therapeutics filed a Form 10-Q for the quarter ended March 31, 2026. The filing includes financial data and disclosures related to derivative liabilities, preferred stock changes (Series C, D, E), equity transactions, fair value adjustments of assets like cash equivalents and short-term investments, and subsequent events including an Almata Bio transaction milestone achieved on April 26, 2026.
Tickers: $AVTX